嵌合抗原受体自然杀伤细胞免疫治疗多发性骨髓瘤研究进展
Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma
查看参考文献56篇
|
文摘
|
尽管新药的进展使多发性骨髓瘤(MM)患者的生存得到明显改善,但复发难治MM仍缺乏有效治疗方案,且预后差。嵌合抗原受体T细胞(CAR-T)免疫治疗技术虽然在复发难治MM中有不错的疗效,但仍存在局限性,如细胞因子释放综合征、神经毒性等不良反应和脱靶效应等。自然杀伤(NK)细胞作为机体固有免疫的重要成分,在肿瘤免疫监视中发挥重要功能,因此基于NK细胞的嵌合抗原受体自然杀伤细胞(CAR-NK)免疫治疗技术也越来越受到关注。目前CAR-NK免疫治疗MM的研究显示,多个靶点可作为CAR-NK免疫治疗技术特异性治疗靶点,并且在MM细胞及动物实验中也证实其抗肿瘤效应。本文总结了MM肿瘤微环境中NK细胞抗肿瘤机制、生物学特点和功能缺陷情况,以及CAR-NK免疫治疗MM的基础和临床研究进展。 |
|
其他语种文摘
|
Although the development of novel drugs has significantly improved the survival of patients with multiple myeloma(MM)over the past decades, the lack of effective therapeutic options for relapsed and refractory MM results in poor prognosis. The chimeric antigen receptor(CAR)T-cell therapy has achieved considerable progress in relapsed and refractory MM. Nevertheless, this therapy still has limitations such as cytokine release syndrome, neurotoxicity, and off-target effects. Natural killer(NK)cells, as a critical component of the innate immune system, play an essential role in tumor immunosurveillance. Therefore, CAR-modified NK(CARNK)cells are put forward as a therapeutic option for MM. The available studies have suggested that multiple targets can be used as specific therapeutic targets for CAR-NK cell therapy and confirmed their antitumor effects in MM cell lines and animal models. This review summarizes the anti-tumor mechanisms, biological characteristics, and dysfunction of NK cells in the MM tumor microenvironment, as well as the basic and clinical research progress of CAR-NK cells in treating MM. |
|
来源
|
中国医学科学院学报
,2023,45(2):290-297 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.14785
|
|
关键词
|
多发性骨髓瘤
;
嵌合抗原受体自然杀伤细胞
;
复发
;
难治
;
治疗
|
|
地址
|
四川大学华西医院血液内科四川大学华西医院血液病研究所, 成都, 610041
|
|
语种
|
中文 |
|
文献类型
|
综述型 |
|
ISSN
|
1000-503X |
|
学科
|
内科学 |
|
基金
|
四川省自然科学基金
;
四川大学华西医院临床研究孵化项目
;
四川大学华西医院成果转化项目
;
四川大学华西医院学科卓越发展1.3. 5工程
;
国家血液系统疾病临床医学研究中心转化研究课题
|
|
文献收藏号
|
CSCD:7470007
|
参考文献 共
56
共3页
|
|
1.
Gandhi U H. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Leukemia,2019,33(9):2266-2275
|
CSCD被引
7
次
|
|
|
|
|
2.
Mikkilineni L. CAR T cell therapies for patients with multiple myeloma.
Nat Rev Clin Oncol,2021,18(2):71-84
|
CSCD被引
15
次
|
|
|
|
|
3.
Munshi N C. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma.
N Engl J Med,2021,384(8):705-716
|
CSCD被引
39
次
|
|
|
|
|
4.
Berdeja J G. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet,2021,398(10297):314-324
|
CSCD被引
27
次
|
|
|
|
|
5.
Xu J. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
Proc Natl Acad Sci USA,2019,116(19):9543-9551
|
CSCD被引
34
次
|
|
|
|
|
6.
Raje N. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
N Engl J Med,2019,380(18):1726-1737
|
CSCD被引
51
次
|
|
|
|
|
7.
Zhao W. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma.
J Hematol Oncol,2018,11(1):141
|
CSCD被引
2
次
|
|
|
|
|
8.
Brudno J N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management.
Blood Rev,2019,34:45-55
|
CSCD被引
47
次
|
|
|
|
|
9.
Wudhikarn K. Future of CAR T cells in multiple myeloma.
Hematology,2020,2020(1):272-279
|
CSCD被引
1
次
|
|
|
|
|
10.
Liu P. Natural killer cell immunotherapy against multiple myeloma: progress and possibilities.
J Leukoc Biol,2018,103(5):821-828
|
CSCD被引
1
次
|
|
|
|
|
11.
Shah U A. CAR T and CAR NK cells in multiple myeloma: expanding the targets.
Best Pract Res Clin Haematol,2020,33(1):101141
|
CSCD被引
3
次
|
|
|
|
|
12.
Liu E. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors.
N Engl J Med,2020,382(6):545-553
|
CSCD被引
58
次
|
|
|
|
|
13.
Tomaipitinca L. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors.
Mol Aspects Med,2021,80:100968
|
CSCD被引
2
次
|
|
|
|
|
14.
崔蕊. 嵌合抗原受体自然杀伤细胞在血液系统恶性肿瘤中的研究进展.
国际生物医学工程杂志,2021,44(1):77-82
|
CSCD被引
1
次
|
|
|
|
|
15.
Cozar B. Tumor-infiltrating natural killer cells.
Cancer Discov,2021,11(1):34-44
|
CSCD被引
27
次
|
|
|
|
|
16.
Chiossone L. Natural killer cells and other innate lymphoid cells in cancer.
Nat Rev Immunol,2018,18(11):671-688
|
CSCD被引
40
次
|
|
|
|
|
17.
Guillerey C. Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.
Cell Mol Life Sci,2016,73(8):1569-1589
|
CSCD被引
2
次
|
|
|
|
|
18.
Zavidij O. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Nat Cancer,2020,1(5):493-506
|
CSCD被引
9
次
|
|
|
|
|
19.
Fionda C. Translating the antimyeloma activity of Natural Killer cells into clinical application.
Cancer Treat Rev,2018,70:255-264
|
CSCD被引
3
次
|
|
|
|
|
20.
Kim S Y. Post-transplantation natural killer cell count: a predictor of acute graft-versus-host disease and survival outcomes after allogeneic hematopoietic stem cell transplantation.
Clin Lymphoma Myeloma Leuk,2016,16(9):527-535
|
CSCD被引
5
次
|
|
|
|
|
了解气象卫星更多信息，请访问